Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
LUDG
Ludwig Enterprises, Inc.
Development of non-invasive diagnostic tests/biomarker-based technology qualifies as medical devices & biometrics.
|
$11.38M |
$0.07
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$11.00M |
$0.94
+1.08%
|
|
LFWD
Lifeward Ltd.
LFWD directly designs, manufactures, and sells medical devices (exoskeletons, anti-gravity systems, and rehabilitation solutions), fitting Medical Devices & Biometrics.
|
$10.84M |
$0.69
-3.89%
|
|
VASO
Vaso Corporation
Vaso develops and sells medical devices and biometrics-related technology (cardiovascular focus).
|
$10.62M |
$0.17
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Lead program targets a rare disease (Netherton Syndrome) and is developed by a biotech focused on rare diseases.
|
$10.57M |
$10.82
+1.55%
|
|
RMSL
REMSleep Holdings, Inc.
RMSL designs and manufactures CPAP-based respiratory medical devices (DeltaWave), directly aligning with 'Medical Devices & Biometrics'.
|
$10.48M |
$0.01
|
|
SEED
Origin Agritech Limited
Origin provides breeding services and collaborative R&D through a service consortium, aligning with Contract Research Organizations.
|
$10.36M |
$1.31
-0.76%
|
|
EDSA
Edesa Biotech, Inc.
EB06 is an anti-CXCL10 monoclonal antibody therapeutic directly developed by Edesa for vitiligo, representing a direct monoclonal antibody product.
|
$10.27M |
$1.45
+2.11%
|
|
CURX
Curanex Pharmaceuticals Inc Common Stock
Lead candidate Phyto-N targets inflammatory diseases, placing CURX in the Biotech - Immunology Therapeutics space.
|
$9.99M |
$0.36
-1.98%
|
|
QURT
Quarta-Rad, Inc.
Geiger counters and radiation-detection devices are diagnostic/instrumentation equipment, mapping to Diagnostic Equipment.
|
$9.96M |
$0.65
|
|
YMAT
J-Star Holding Co., Ltd. Ordinary Shares
Produces medical device components used in healthcare applications, reflecting a direct product line.
|
$9.86M |
$0.53
+0.19%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$9.82M |
$1.05
-15.32%
|
|
SINT
Sintx Technologies, Inc.
Core business is manufacturing medical-grade silicon nitride materials used in medical devices, aligning with Medical Devices & Biometrics.
|
$9.63M |
$3.54
+1.43%
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$9.59M |
$2.67
+5.53%
|
|
CUPR
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
MEDIFLY maggot debridement therapy is Cuprina's flagship wound care device/product.
|
$9.57M |
$0.45
-2.71%
|
|
CHEK
Check-Cap Ltd.
Check-Cap historically manufactured medical devices and biometric sensing technologies, including C-Scan components.
|
$9.42M |
$1.63
+1.24%
|
|
XTLB
XTL Biopharmaceuticals Ltd.
Core focus on autoimmune immunology therapeutics with lead asset hCDR1.
|
$9.34M |
$0.99
+1.44%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$9.28M |
$1.21
+2.12%
|
|
BRTX
BioRestorative Therapies, Inc.
BRTX-100 is an autologous mesenchymal stem cell therapy, the company's lead cell therapy product for disc disease.
|
$9.17M |
$1.15
|
|
EVGN
Evogene Ltd.
Biomica's microbiome therapeutics program (BMC128) targets human health, fitting Immunology Therapeutics within Biotech.
|
$9.15M |
$1.05
+0.48%
|
|
IMNN
Imunon, Inc.
IMUNON's lead candidate IMNN-001 targets ovarian cancer, aligning with Biotech - Oncology.
|
$9.10M |
$4.16
+0.73%
|
|
BIVI
BioVie Inc.
Bezisterim is described as an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, aligning with 'Oral Small Molecule Therapeutics'.
|
$9.08M |
$1.22
+2.97%
|
|
EPIX
ESSA Pharma Inc.
Directly describes a biotech company focused on oncology drug development (masofaniten) with no revenue; core business is cancer therapeutics.
|
$8.93M |
$0.20
|
|
XAIR
Beyond Air, Inc.
LungFit is a medical device platform that generates nitric oxide and is sold/distributed to hospitals.
|
$8.88M |
$1.72
-0.29%
|
|
AIMD
Ainos, Inc.
VELDONA human therapeutic programs target rare diseases, aligning with Biotech - Rare Diseases.
|
$8.85M |
$1.96
+1.55%
|
|
TNON
Tenon Medical, Inc.
Catamaran SI Joint Fusion System and related SI implants are orthopedic devices sold as implants for sacroiliac fusion.
|
$8.83M |
$0.95
+0.07%
|
|
PTHL
Pheton Holdings Ltd Class A Ordinary Shares
The company operates a software-driven planning/diagnostic workflow used in radiology/medical imaging, which can be associated with the diagnostic equipment category.
|
$8.68M |
$0.88
-2.48%
|
|
SCNX
Scienture Holdings, Inc.
Arbli (SCN-102) is a cardiovascular drug (losartan liquid formulation) indicated for hypertension and related conditions.
|
$8.55M |
$0.52
-0.54%
|
|
HSCS
HeartSciences Inc.
HeartSciences develops medical devices (wavECG) and biometric sensing capabilities, aligning with Medical Devices & Biometrics.
|
$8.47M |
$3.21
+0.31%
|
|
BCDA
BioCardia, Inc.
CardiAMP and CardiALLO are BioCardia's direct cell-therapy programs (autologous and allogeneic) targeted for cardiovascular disease.
|
$8.41M |
$1.46
+0.34%
|
|
LGVN
Longeveron Inc.
LGVN's lead candidate laromestrocel is a mesenchymal stem cell (MSC) therapy, directly aligning with Biotech - Cell Therapy.
|
$8.38M |
$0.56
-1.22%
|
|
TSBX
Turnstone Biologics Corp.
Company's core business is oncology-focused biotechnology, including immunotherapy approaches (TIL-based strategies) in solid tumors.
|
$8.21M |
$0.35
|
|
BCTX
BriaCell Therapeutics Corp.
BriaCell develops off-the-shelf allogeneic cell therapies (Bria-IMT) and a cell-therapy platform (Bria-OTS).
|
$8.08M |
$4.30
-4.12%
|
|
MBIO
Mustang Bio, Inc.
Develops cell therapy products, primarily CAR T therapies (cell-based immunotherapies).
|
$7.60M |
$1.05
+0.48%
|
|
RNAZ
TransCode Therapeutics, Inc.
Company focuses on RNA interference (RNAi) therapeutics, including siRNA/miRNA-targeted programs.
|
$7.45M |
$8.77
-0.74%
|
Showing page 34 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
